Thrivent International Allocation Fund

901 Marquette Avenue,Suite 2500
Minneapolis , MN, 55402-3211

Rank

Rank Universe

Summary

The fund seeks capital appreciation in the long term by investing in companies across any size outside the United States.

The sub-adviser’s investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team focuses on securities of issuers throughout the world, and invest More

Link

Directors

Jan 10, 2024
  • Constance L. Souders
  • Janice B. Case
  • Paul R. Laubscher
  • Robert J. Chersi
  • Arleas Upton Kea
  • Robert J. Manilla
  • David S. Royal
  • James W. Runcie
  • Michael W. Kremenak
  • James A. Nussle

Chief Compliance Officer

  • Edward S. Dryden

Fund Manager(s)

Price

  • $ 10.29 ( -0.02 )
    Dec 31, 2024
    Last Close
  • Net Assets
  • $778.1M
    Mar 27, 2024
  • Holding
  • 337
    Sep 25, 2024
    More

  • 52-Week High/Low
  • $11.54 - $9.85
  • Turnover
  • 92%
  • Expense Ratio
  • 1.34%

Company Name

Holding

Novartis Ag Basel 2.33 %
Astrazeneca Plc 1.78 %
Canadian National Railway Co 1.14 %
Relx Plc 1.01 %
DBS Group Holdings Ltd 0.93 %
Auto Trader Group Plc 0.89 %
Banco Bilbao Vizcaya Argentaria, S.A. 0.7 %
Sony Corp 0.69 %
GIVaudan Sa 0.68 %
Koninklijke Ahold Delhaize N V 0.67 %
More 0.67 %

Advisor

Documents

Prospectus

Annual Reports

Performance

YTD

-

3 Year

-7.38%

5 Year

-1.44%

Best

31.26%

2009

Worst

-19.98%

2022

Alpha

TWAAX S&P 500

Chart +